Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2011-2189PMID 22170708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

  2011cited by this paper
• Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

  2011cited by this paper
• Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

  2010cited by this paper
• Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS)

  2010cited by this paper
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

  2010cited by this paper
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

  2010cited by this paper
• Steroid hormone receptors in prostate cancer: a hard habit to break?

  2009cited by this paper
• Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

  2009cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

  2008cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008cited by this paper
• Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

  2008cited by this paper
• CYP17 inhibition as a hormonal strategy for prostate cancer

  2008cited by this paper
• Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer

  2007cited by this paper
• Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

  2004cited by this paper
• The backdoor pathway to dihydrotestosterone.

  2004cited by this paper
• Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.

  2004cited by this paper
• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

  2004cited by this paper
• Overview of dehydroepiandrosterone biosynthesis.

  2004cited by this paper
• 5α-androstane-3α, 17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α, 17α-diol-20-one as a key intermediate

  2003cited by this paper
• 5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate.

  2003cited by this paper
• The genetics, pathophysiology, and management of human deficiencies of P450c17.

  2001cited by this paper
• Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors.

  1998cited by this paper
• Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

  1995cited by this paper
• Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

  1994cited by this paper
• Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)

  1994cited by this paper
• Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture.

  1988cited by this paper
• Profiling steroid hormones and urinary steroids.

  1986cited by this paper

• New Human CYP17A1 Fluorescent Ligands

  2026cites this paper
• Dihydrotanshinone as a Natural Product-Based CYP17A1 Lyase Inhibitor for Hyperandrogenic Disorders

  2026cites this paper
• Approved Steroidal Drugs (2000-2025): A Medicinal Chemistry Perspective.

  2026cites this paper
• Nouvelles avancées thérapeutiques dans la prise en charge de l’hyperplasie congénitale des surrénales par déficit en 21-hydroxylase

  2026cites this paper
• The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials

  2025cites this paper
• Severe Presentation of De Novo Type II Diabetes in Abiraterone and Prednisone Therapy

  2025cites this paper
• Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial

  2025cites this paper
• Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals

  2025cites this paper
• Characterization of an NADPH-dependent 17α-hydroxysteroid dehydrogenase encoded by the desF gene from the gut bacterium Clostridium scindens VPI 12708

  2025cites this paper
• Sarcopenia in mCSPC: Beyond Radiological Metrics-The Need for Functional and Supportive Assessments.

  2025cites this paper
• The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data

  2025cites this paper
• Finding the cause of severe hypokalemia: A 4-step approach

  2025cites this paper
• Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy

  2025cites this paper
• A New ERA for radium-223? Optimizing Treatment by Balancing Efficacy and Toxicity Through Combination Therapies.

  2025cites this paper
• EFFECTIVENESS OF BISPHOSPHONATES AND DENOSUMAB ON RISK OF VERTEBRAL FRACTURES IN PROSTATE CANCER PATIENTS UNDER ANDROGEN-DEPRIVATION THERAPIES: A REAL-WORLD PROSPECTIVE STUDY.

  2025cites this paper
• Clinical impact of real‐time androgen receptor alteration monitoring on metastatic castration‐resistant prostate cancer treatment in real‐world settings

  2025cites this paper
• Navigating the Complexities of Cancer Treatment-Induced Hypertension

  2025influential citation
• Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.

  2024cites this paper
• Abiraterone-Induced Secondary Hypertension: Two Wrongs Don’t Make a Right

  2024cites this paper
• Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology

  2024cites this paper
• Formulating abiraterone acetate-HPMCAS-based amorphous solid dispersions: insights into in vitro and biorelevant dissolution assessments and pharmacokinetic evaluations

  2024cites this paper
• 2024 Clinical practice guidelines for Hypertension in adults

  2024cites this paper
• Synthesis and Biological Evaluation of Methoxypolyethylene-Glycol-Substituted Abiraterone Derivatives as Potential Antiprostate Cancer Agents.

  2024cites this paper
• Abiraterone-Associated Mineralocorticoid Excess: A Case Report

  2024influential citation
• Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study

  2024cites this paper
• Androgen deprivation therapy and cardiological risks in patients with prostate cancer. Are all drugs the same?

  2024cites this paper
• Abiraterone in Classic Congenital Adrenal Hyperplasia: Results of Medical Therapy Before Adrenalectomy

  2024cites this paper
• Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids

  2024cites this paper
• Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

  2024cites this paper
• Deciphering the genetic and epigenetic architecture of prostate cancer.

  2024cites this paper
• Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer

  2024cites this paper
• Abiraterone-Induced Endocrinopathies

  2023cites this paper
• Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer.

  2023cites this paper
• Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

  2023cites this paper
• Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy

  2023cites this paper
• Exploring the Chemical Space of CYP17A1 Inhibitors Using Cheminformatics and Machine Learning

  2023cites this paper
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

  2023cites this paper
• Diagnostic et prise en charge de l’hypertension artérielle sous traitements anticancéreux

  2023cites this paper
• How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?

  2023cites this paper
• Abdominal pain in a patient with epistaxis, telangiectasias, and arteriovenous malformations

  2023cites this paper
• Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

  2022cites this paper
• Steroidogenesis in castration-resistant prostate cancer.

  2022cites this paper
• The Potential Role of Exosomal Proteins in Prostate Cancer

  2022cites this paper
• Adrenal steroids and resistance to hormonal blockade of prostate and breast cancer.

  2022cites this paper
• Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling

  2022cites this paper
• The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer.

  2022cites this paper
• 17α-Hydroxylase/17,20-Lyase Deficiency in 46,XY: Our Experience and Review of Literature

  2022cites this paper
• Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice

  2022cites this paper
• [The interactions of abiraterone and its pharmacologically active metabolite D4A with cytochrome P450 2C9 (CYP2C9)].

  2022cites this paper
• Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.

  2022cites this paper
• Interaction of Abiraterone and Its Pharmacologically Active Metabolite D4A with Cytochrome P450 2C9 (CYP2C9)

  2022cites this paper
• Androgen receptor mutations for precision medicine in prostate cancer.

  2022cites this paper
• Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment

  2022cites this paper
• Inhibition of Cytochrome P450 Enzymes by Drugs—Molecular Basis and Practical Applications

  2021cites this paper
• Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer

  2021cites this paper
• Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.

  2021cites this paper
• Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study

  2021cites this paper
• Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer

  2021cites this paper
• Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.

  2021cites this paper
• Bone Health in Cancer Patients

  2021cites this paper
• Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease

  2021cites this paper
• Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment—A Cardio-Oncology Study

  2021cites this paper
• Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

  2021cites this paper
• Hormonal Therapy for Prostate Cancer.

  2021cites this paper
• Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

  2021cites this paper
• Steroidogenic Cytochrome P450 17A1 Structure and Function.

  2021cites this paper
• The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice

  2021cites this paper
• Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide

  2021cites this paper
• Second-generation hormonotherapy in prostate cancer and bone microenvironment.

  2021cites this paper
• Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2).

  2020cites this paper
• Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

  2020cites this paper
• Intracrinology-revisited and prostate cancer.

  2020cites this paper
• Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses

  2020cites this paper
• Sex Hormones and Prostate Cancer.

  2020cites this paper
• The role of adrenal derived androgens in castration resistant prostate cancer.

  2020cites this paper
• In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug–drug interactions

  2020cites this paper
• A Phase 2 Study of Seviteronel (INO-464) in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Enzalutamide Treatment

  2020cites this paper
• Cardiovascular Complications of Prostate Cancer Treatment

  2020cites this paper
• Interactions of galeterone and its 3‐keto‐Δ4 metabolite (D4G) with one of the key enzymes of corticosteroid biosynthesis – steroid 21‐monooxygenase (CYP21A2)

  2020cites this paper
• Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy

  2020cites this paper
• Improving Solubility of Poorly Soluble Abiraterone Acetate by Cocrystal Design Aided by In Silico Screening

  2020cites this paper
• Secondary Hypertension

  2020cites this paper
• Germline HSD3B1 Genetics and Prostate Cancer Outcomes.

  2020cites this paper
• Drug-Induced Hypertension

  2020cites this paper
• Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.

  2020cites this paper
• Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer

  2020cites this paper
• Role of Cytochrome P450 in Prostate Cancer and its Therapy

  2020cites this paper
• Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice

  2020cites this paper
• Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.

  2020cites this paper
• Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer

  2020cites this paper
• Abiraterone acetate treatment lowers 11-oxygenated androgens.

  2020cites this paper
• Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis

  2019cites this paper
• Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.

  2019cites this paper
• Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

  2019cites this paper
• Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer

  2019cites this paper
• A novel mutation in CYP17A1 gene leads to congenital adrenal hyperplasia: A case report

  2019cites this paper
• The Effect of Soy Isoflavones on Steroid Metabolism

  2019cites this paper
• Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate.

  2019cites this paper
• Emerging therapeutic agents for genitourinary cancers

  2019cites this paper
• Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.

  2019cites this paper